Key result
Double-port totally endoscopic MVR shows feasibility with ~1% early mortality.
Why the study?
To evaluate the feasibility and early outcomes of totally endoscopic non-robotic mitral valve replacement using a double-port DCT approach with posterior subvalvular preservation.
Is double-port totally endoscopic non-robotic mitral valve replacement feasible and safe in patients requiring mitral valve replacement?
Observational (n=76)
No
Is double-port totally endoscopic non-robotic mitral valve replacement feasible and safe in patients requiring mitral valve replacement?
The double-port totally endoscopic non-robotic mitral valve replacement technique is feasible and safe in the short term, offering a minimally invasive option for patients requiring valve replacement.
Supports short-term feasibility of double-port endoscopic non-robotic MVR; hypothesis-generating and requires randomized trials before practice change.
Objective: To evaluate the feasibility and early outcomes of totally endoscopic non-robotic mitral valve replacement using a double-port DCT approach with posterior subvalvular preservation. Methods: In this single-center retrospective observational study, 76 consecutive patients underwent totally endoscopic non-robotic mitral valve replacement between November 2023 and December 2025. The DCT approach was defined by exclusive endoscopic visualization, no rib spreading, a camera port and prosthesis-sized working incision placed in the same intercostal space, and thoracoscopic intracardiac instrumentation. Posterior ventricular-annular continuity was preserved whenever feasible by posterior leaflet preservation, native chordal preservation, or artificial chordal reimplantation after leaflet resection. Outcomes were reported descriptively with 95% confidence intervals. Results: Mechanical prostheses were implanted in 46 patients (60.5%) and bioprostheses in 30 (39.5%). Mean skin incision length was 3.8 ± 0.5 cm. Mean cardiopulmonary bypass and aortic cross-clamp times were 148.3 ± 38.6 and 101.9 ± 32.0 minutes, respectively. There was 1 early non-cardiac death (1.3%; 95% CI, 0.03%-7.1%), no late death, and no mitral valve reoperation (0%; 95% CI, 0%-4.7%). No moderate or severe paravalvular regurgitation was observed during early echocardiographic follow-up. Mean follow-up was 9.7 ± 6.0 months. Freedom from prosthetic valve-related adverse events was 98.6% (95% CI, 90.6%-99.8%) at 6 months and 95.2% (95% CI, 80.1%-98.9%) at 12 months. The 24-month estimate was identical but was based on few patients at risk and should be interpreted cautiously. Conclusions: The double-port DCT approach was technically feasible and was associated with acceptable early clinical and echocardiographic outcomes. Because of the retrospective single-center design, small sample size, absence of a comparator group, and short follow-up, these findings should be interpreted as feasibility data rather than evidence of superiority.
No takes yet. Share an insight, caveat, or question.
Khang et al. (2026) conducted an observational in Mitral valve pathology requiring replacement (n=76). Double-port totally endoscopic non-robotic mitral valve replacement (DCT approach) was evaluated on Early mortality (95% CI 0.03-7.1). Double-port totally endoscopic non-robotic mitral valve replacement was technically feasible with 1.3% early mortality and no moderate or severe paravalvular regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: